Against a backdrop of limited efficacy from MEK inhibition [14] and a need to suppress pathway activation, particularly in view of current considerations for including FLT3 inhibitors to frontline AML treatment regimens [15], there is a continued need to explore novel and potent pathway inhibitors. This evidence concerns the gene MAP2K7 and acute myeloid leukemia.